当前期刊: Leukemia Supplements Go to current issue    加入关注   
显示样式:        排序: 导出
我的关注
我的收藏
您暂时未登录!
登录
  • Mechanisms of graft-versus-leukemia effects after allogeneic stem cell transplantation: effects on the leukemia stem cell?
    Leuk. Suppl. Pub Date : 2014-12-17
    H-J Kolb, H Schmetzer, C Schmid, I Bigalke, R Buhmann, A Moosmann, C Falk, S Reuther, F Schuster, A Borkhardt
    更新日期:2019-11-18
  • 更新日期:2019-11-18
  • Challenges in multiple myeloma diagnosis and treatment
    Leuk. Suppl. Pub Date : 2013-05-08
    S Girnius, N C Munshi

    Although multiple myeloma (MM) remains an incurable disease, the advent of novel treatment paradigms has improved survival outcomes in the past two decades. This includes widespread use of high-dose chemotherapy with autologous stem cell transplantation (HDT–ASCT) and the development of the novel agents thalidomide, lenalidomide and bortezomib. The efficacy and tolerability of these novel agents have allowed for the exploration of continuous therapy approaches. Maintenance therapy after HDT–ASCT, for example, may help prolong progression-free survival by providing sustained control of residual disease. Trials are also under way to evaluate lenalidomide in patients with high-risk smoldering MM, with the aim of delaying progression to symptomatic MM. Other research is focusing on improving HDT–ASCT protocols and integrating novel agents, such as bortezomib, as an induction or consolidation therapy. Despite these advances, more effective strategies are needed, particularly for the management of older, less fit patients who are ineligible for HDT–ASCT. Preliminary results on the use of lenalidomide maintenance therapy in elderly patients are encouraging. Taken together, these observations indicate that in this era of novel agents, optimal treatment of MM requires a long-term perspective that focuses on providing sustained disease control while maintaining quality of life.

    更新日期:2019-11-18
  • Optimizing outcomes for patients with newly diagnosed multiple myeloma eligible for transplantation
    Leuk. Suppl. Pub Date : 2013-05-08
    P Moreau, C Touzeau

    High-dose therapy with autologous stem cell transplantation (HDT–ASCT) has been considered to be the standard frontline treatment for younger, fit patients with multiple myeloma (MM) since the 1990s. Efforts continue to optimize the use of HDT–ASCT with the aim of improving outcomes. One strategy has been the incorporation of novel agents (thalidomide, lenalidomide and bortezomib) in the pre-transplantation setting as an induction therapy or in the post-transplantation setting as a consolidation or maintenance therapy. Given their high response rates, three-drug induction therapy regimens (for example, bortezomib–thalidomide–dexamethasone, lenalidomide–bortezomib–dexamethasone and cyclophosphamide–bortezomib–dexamethasone) are now the standard of care. Thalidomide and bortezomib are well suited for consolidation therapy, and regimens using these agents can improve the depth of response following HDT–ASCT. Lenalidomide is particularly well suited for long-term maintenance therapy following HDT–ASCT, and initial results are promising and have shown improvements in disease outcomes such as progression-free survival and overall survival in some cases, although a low incidence of second primary malignancies have been observed. Further studies are needed to determine the optimal regimen and duration of induction therapy, the impact of maintenance on overall survival and the safety of long-term treatment. Many of the studies currently underway in MM will help address these aspects.

    更新日期:2019-11-18
  • Stem cell transplantation for multiple myeloma: current and future status
    Leuk. Suppl. Pub Date : 2013-05-08
    S Giralt, W Bensinger

    Stem cell transplantation (SCT) has been used in the treatment of multiple myeloma (MM) for decades and has become a standard of care for newly diagnosed MM patients. However, several important questions remain regarding the optimal use of SCT, particularly in light of the many recent advances in the treatment of MM. Bortezomib-based therapy or, in some cases, lenalidomide-based therapy should be considered as an induction therapy in transplantation-eligible patients. Efforts to improve upon the efficacy and safety of standard transplantation regimens (that is, high-dose melphalan) are also underway. Most published studies on the use of tandem autologous SCT were conducted before the advent of novel agents, such as thalidomide, lenalidomide and bortezomib, making it difficult to establish the current role of tandem SCT. Allogeneic SCT continues to be evaluated in clinical trials, and may have an important role in the treatment of transplantation-eligible patients with suitable donors. Post-transplantation consolidation and maintenance therapy using novel agents should be considered to improve outcomes in patients who fail to achieve a complete response following SCT. Patients in remission should be advised that continued therapy has been shown to prolong remission, improve quality of life and extend survival. Additional data on the optimal approach to post-transplantation therapy are needed. New strategies in development aimed at improving patient selection, safety and efficacy of SCT are likely to improve future outcomes.

    更新日期:2019-11-18
  • Advances in treatment for newly diagnosed multiple myeloma patients ineligible for autologous stem cell transplantation
    Leuk. Suppl. Pub Date : 2013-05-08
    J F San Miguel, M-V Mateos

    The majority of newly diagnosed multiple myeloma patients are over 65 years and/or physically unfit, and, therefore, are not eligible for standard treatment with high-dose chemotherapy and stem cell transplantation. The treatment goals in these patients should be to ensure improvement in disease management and to prolong survival while ensuring quality of life. Until recently, treatment options for such patients were limited, but new treatment combinations based on the novel agents thalidomide, bortezomib and lenalidomide have improved outcomes and survival. Moreover, phase III data indicate that maintenance treatment with novel agents may contribute to extended progression-free survival; however, the optimal duration of long-term therapy has not yet been defined. The potential for novel treatment regimens to improve the adverse prognosis associated with high-risk cytogenetic profiles, such as deletion 17p, also requires further research. Elderly patients, particularly those over 75 years and the clinically vulnerable, require close monitoring and individualized, dose-modified regimens to improve tolerability and treatment efficacy, while maintaining quality of life.

    更新日期:2019-11-18
  • Antibiotic therapy in hematological neutropenic patients: what is the news?
    Leuk. Suppl. Pub Date : 2012-08-09
    F Pea

    Bacterial infection is a very common complication in hematological neutropenic patients whose treatment is extremely challenging for several reasons. First, they are frequently caused by resistant pathogens (multidrug resistant (MDR)), and this may limit the availability of effective therapeutic weapons. Second, these patients often present peculiar pathophysiological conditions that may alter the pharmacokinetic behavior of antimicrobials, and this may explain the need for a new administration schedule and new dosing regimens of antibiotics in this setting. In an era in which there are only few new therapeutic weapons for the treatment of MDR bacterial infections, while advocating for new drugs, what could be effectively done nowadays is to increase the knowledge on appropriateness of the use of currently available drugs to improve clinical outcome and to preserve their activity.

    更新日期:2019-11-18
  • Viral infections in patients with hematological malignancies
    Leuk. Suppl. Pub Date : 2012-08-09
    A Busca

    Viral infections remain one of the most frequent complications in patients with hematological malignancies, especially in those receiving an allogeneic stem cell transplantation. Viral infections result from reactivation of latent infection rather than from acquisition of new infection. Infections caused by herpes viruses, including cytomegalovirus and Epstein-Barr virus, respiratory viruses and hepatitis B virus are frequently associated with high morbidity and mortality in the immunocompromised host. Major advances have been made primarily by the availability of rapid diagnostic tests and the introduction of potent antiviral compounds into clinical practice.

    更新日期:2019-11-18
  • Prognostic factors in CLL
    Leuk. Suppl. Pub Date : 2012-08-09
    M Ferrarini, G Cutrona, A Neri, F Morabito

    Chronic lymphocytic leukemia (CLL) is a clinically heterogeneous disease, as some patients progress rapidly toward the more advanced studies, whereas others survive for a long period without the need for treatment. This heterogeneity of clinical course was somehow unexplained until studies on the CLL cell features disclosed that the CLL clones were heterogeneous and were characterized by different phenotypic and genotypic features in the different patients. On the basis of these observations, it was determined in retrospective studies that clones characterized by unmutated IGHV genes, and/or CD38 and/or ZAP-70 expression conferred a more severe prognosis to the CLL patients. Here, we present data on prospective studies carried out on Binet A-stage patients, in whom the markers were determined at diagnosis and their predictive value was assessed in comparison with chromosomal abnormalities and gene expression or micro RNA profiles. In addition, hypothesis on the potential pathogenetic role of these markers will be presented.

    更新日期:2019-11-18
  • Initial treatment for patients with chronic myeloid leukemia
    Leuk. Suppl. Pub Date : 2012-08-09
    M Baccarani

    The first-line treatment of chronic myeloid leukemia is based on the three currently available tyrosine kinase inhibitors (TKIs), namely imatinib, nilotinib and dasatinib. Nilotinib and dasatinib are more potent, and it is predicted that, in comparison with imatinib, they can reduce the risk of progression and increase the number of the patients who can discontinue the treatment without relapsing. Other TKIs are still being developed and may help to improve treatment options further on. Hydroxyurea has no longer a role. Allogeneic stem cell transplantation is the treatment of choice for the advanced phases, and in case of resistance to at least two TKIs.

    更新日期:2019-11-18
  • Challenges for the next decade: allogeneic stem cell transplantation in chronic lymphocytic leukemia
    Leuk. Suppl. Pub Date : 2012-08-09
    P Corradini, L Farina

    Although hematopoietic stem cell transplantation (allogeneic SCT (allo-SCT)) is the treatment of choice for many aggressive hematological malignancies, the role of allo-SCT in chronic lymphocytic leukemia (CLL) is still a matter of debate and can be considered one of the more important challenges for the next decade. In the era of novel drugs and humanized antibodies, the long-term outcome of patients has improved, and a critical reappraisal of autologous and allo-SCT in CLL treatment is warranted.

    更新日期:2019-11-18
  • Biology of CML stem cells: the basis for clinical heterogeneity?
    Leuk. Suppl. Pub Date : 2012-08-09
    J M Goldman, M Gordon, A Bazeos, D Marin
    更新日期:2019-11-18
  • Inhibition of autophagy with clarithromycin: a new strategy to enhance sensitivity of CML stem cells to tyrosine kinase inhibitors
    Leuk. Suppl. Pub Date : 2012-08-09
    A M Carella, G Beltrami, G Catania, G Pica, C Ghiggi, A Garuti, A Carella

    Autophagy inhibition has been shown to sensitize tumor cells to cell death induced by tyrosine kinase inhibitors (TKIs). The remarkable responses obtained in seven patients with the combination of clarithromycin and TKIs support the hypothesis that the inhibition of autophagy may make chronic myeloid leukemia cells sensitive to killing by TKIs.

    更新日期:2019-11-18
  • Normal and leukemic stem cells
    Leuk. Suppl. Pub Date : 2012-08-09
    P G Pelicci

    Studies on hematopoietic stem cells have provided several critical insights in the biology of stem cells in general; as mature blood cells are generally short lived, stem cells are in fact required to guarantee, throughout the life of an organism, the replenishment of differentiated blood cells by the generation of multi-lineage progenitors and precursors committed to individual hematopoietic lineages. Similarly, acute myeloid leukemia has been considered as a model system to study cancer stem cells. This presentation illustrates some recent results obtained by our group with regard to both normal and leukemic stem cells.

    更新日期:2019-11-18
  • Change in prognostic factors
    Leuk. Suppl. Pub Date : 2012-08-09
    D Hoelzer, N Gökbuget
    更新日期:2019-11-18
  • Modern therapy of young and adult Ph-ALL
    Leuk. Suppl. Pub Date : 2012-08-09
    R Bassan, T Intermesoli, O Spinelli, E Oldani, A Rambaldi
    更新日期:2019-11-18
  • Advances in unrelated cord blood transplants in malignancies
    Leuk. Suppl. Pub Date : 2012-08-09
    E Gluckman

    Cord blood is an unlimited source of hematopoietic stem cells (HSCs) for allogeneic HSC transplant. Since the first human cord blood transplant performed 20 years ago, cord blood banks have been established worldwide for collection and cryopreservation of cord blood for allogeneic HSC transplant. More than 500 000 cord blood units are now available for international exchange of cord blood units. A global network of cord blood banks and transplant centers has been established for a common inventory and study of clinical outcomes. Results of unrelated allogeneic cord blood transplants in malignant and nonmalignant diseases, in adults and children, show that, compared with HLA-matched unrelated bone marrow transplant, cord blood has several advantages including prompt availability of the transplant, decrease of graft versus host disease and better long-term immune recovery resulting in a similar long-term survival. Several studies have shown that the number of cells is the most important factor for engraftment while some degree of HLA mismatches is acceptable. Progresses in this field are expected to facilitate engraftment including ex vivo expansion of stem cells, intra-bone injection of cord blood cells and double cord blood transplants.

    更新日期:2019-11-18
  • Optimal induction and post-remission therapy for acute myeloid leukemia
    Leuk. Suppl. Pub Date : 2012-08-09
    A K Burnett

    The approach to treatment of acute myeloid leukemia is substantially influenced by the age of the patient. Younger patients who are arbitrarily defined as those being <60 years, although comprising the minority of all patients with the disease, will always receive an intensive approach, whereas in older patients, an initial decision as to whether an intensive approach is appropriate or not has to be made. Standard chemotherapy for many years has been ‘3+7’, followed by consolidation with high-dose Ara-C at a daily dose level of 3 g/m2. It remains unclear as to what number of total treatment courses is optimal. Alternatives to this standard of care will be considered.

    更新日期:2019-11-18
  • Novel strategies in treatment of acute promyelocytic leukemia
    Leuk. Suppl. Pub Date : 2012-08-09
    F Lo-Coco, L Cicconi

    Acute promyelocytic leukemia (APL) is a subtype of acute myeloid leukemia characterized by t(15;17) and a life-threatening coagulopathy. Once highly fatal, nowadays standard treatment approaches with all-trans retinoic acid (ATRA) along with chemotherapy allows curing up to 80–85% of cases. In the past decade, arsenic trioxide used alone or in combination with ATRA has demonstrated high efficacy in APL, and is currently regarded as the gold standard for treatment of relapsed cases. Chemotherapy-free approaches based on the combination of arsenic trioxide and ATRA are currently being tested against standard ATRA and chemotherapy in randomized clinical trials for frontline therapy of APL.

    更新日期:2019-11-18
  • Fungal infections: diagnostic problems and choice of therapy
    Leuk. Suppl. Pub Date : 2012-08-09
    B E de Pauw

    Fungi are typically opportunistic pathogens. Formerly, limitations in diagnostic techniques explain why invasive fungal infections are usually detected in a late stage of their development. Therefore, traditional guidelines dictate antifungal treatment for all patients with persisting fever. This is not longer justifiable in view of the potential adverse events and the economical burden associated with the use of the new antifungal drugs in an era with improved diagnostic tools. Amphotericin B has been the drug of choice for invasive fungal infections for more than 30 years. Owing to nephrotoxicity, its use in neutropenic patients has been largely abandoned in favor of a lipid formulation of amphotericin B, of which only liposomal amphotericin B has been scientifically tested in the first-line treatment of aspergillosis. Azoles constitute an acceptable alternative to intravenous amphotericin B for many invasive fungal infections.

    更新日期:2019-11-18
  • The genome of chemorefractory chronic lymphocytic leukemia reveals frequent mutations of NOTCH1 and SF3B1
    Leuk. Suppl. Pub Date : 2012-08-09
    D Rossi, S Rasi, V Spina, A Bruscaggin, S Monti, S Cresta, R Famà, C Deambrogi, M Greco, M Fangazio, C Ciardullo, D Piranda, G M Casaluci, M Messina, I D Giudice, S Chiaretti, M Marinelli, A Guarini, R Foà, G Gaidano

    Next-generation whole-exome sequencing has revealed two novel genes, namely NOTCH1 and SF3B1, whose mutations predict poor outcome and preferentially associate with chemorefractory chronic lymphocytic leukemia (CLL). Analysis of 539 CLL cases documents that NOTCH1 mutations i) represent one of the most frequent cancer gene mutations involved at presentation; ii) cluster with cases harboring trisomy 12 and tend to be mutually exclusive with TP53 disruption among genetic subgroups; iii) identify high-risk patients showing poor survival similar to that associated with TP53 abnormalities; and iv) exert a prognostic role independent of widely accepted clinical and genetic risk factors. Mutations of SF3B1, a splicing factor that is a critical component of the spliceosome, recurrently associate with fludarabine-refractory CLL, occur at a low rate at CLL presentation and have a minor role in Richter transformation, corroborating the notion that CLL histological shift is molecularly distinct from chemorefractory progression without the Richter transformation.

    更新日期:2019-11-18
  • Molecular basis of myelodysplastic syndromes
    Leuk. Suppl. Pub Date : 2012-08-09
    M Cazzola

    Myelodysplastic syndromes (MDS) are myeloid neoplasms characterized by dysplasia in one or more cell lines, ineffective hematopoiesis and variable risk of progression to acute myeloid leukemia. In the past few years, important steps have been taken in characterizing the molecular basis of MDS. More recently, somatic mutations in genes encoding core components of the RNA splicing machinery have been detected in high proportions of MDS patients, and are shown to be founding mutations in many instances. These mutations have different clinical significance, and their incorporation into current stratification systems might improve risk assessment in MDS.

    更新日期:2019-11-18
  • Chronic lymphocytic leukemia: treatment of relapse
    Leuk. Suppl. Pub Date : 2012-08-09
    M Montillo

    Despite significant advances in the frontline treatment of chronic lymphocytic leukemia (CLL), patients eventually experience disease progression. Treatment selection of relapsed disease depends upon a variety of factors, including patient age, performance status, duration of response to initial therapy, type of prior therapy, disease-related manifestations and genetic abnormalities within the CLL cells. This presentation offers synthetic overview of the options in this field.

    更新日期:2019-11-18
  • Second-generation TKIs: which and when?
    Leuk. Suppl. Pub Date : 2012-08-09
    G Saglio

    Impressive response rates and good tolerability have led imatinib 400 mg once a day to become the standard frontline therapy for chronic myeloid leukemia (CML) patients. However, approximately one-third of the treated patients do not respond in an optimal manner to this drug, and the appropriate type and rhythm of CML monitoring, as well as the correct action to be undertaken in case of failure or suboptimal responses to imatinib therapy have been published in specific recommendations by European Leukemia Net and National Comprehensive Cancer Network. Failure and also cytogenetic suboptimal responses strongly demand for a change in treatment and for a switch from imatinib to one of the two second-generation tyrosine kinase inhibitors (TKIs) so far registered, dasatinib and nilotinib, for which efficacy as second-line therapy in imatinib-resistant or intolerant cases has been clearly demonstrated in phase II studies, and for which 4-year updates are now available. Other TKIs, at the moment, still under clinical investigation for imatinib-resistant patients include bosutinib and the next-generation TKI ponatinib. Different efficacy and safety criteria characterize each of the mentioned compounds and may help to decide on the one to be preferably used in individual patients.

    更新日期:2019-11-18
  • Stem cell persistence in chronic myeloid leukemia
    Leuk. Suppl. Pub Date : 2012-08-09
    M Deininger

    Tyrosine kinase inhibitors (TKIs) of BCR-ABL have turned chronic myeloid leukemia (CML) from a deadly disease into a chronic ailment. Unfortunately, evidence is accumulating that TKIs are not curative, since CML stem cells are not addicted to BCR-ABL, and persist despite TKI therapy. On closer view this is not surprising, as it reflects fundamental principles of CML pathogenesis. Strategies to eradicate CML stem cells will most likely be based on synthetic lethality though parallel inhibition of BCR-ABL and other critical pathways.

    更新日期:2019-11-18
  • Where are we going with CML research?
    Leuk. Suppl. Pub Date : 2012-08-09
    D Perrotti

    The introduction of Abl tyrosine kinase inhibitors (TKI; that is, imatinib, dasatinib and nilotinib) as front-line therapy completely changed the course of chronic myelogenous leukemia (CML) to the point that most of the TKI-responsive newly diagnosed CML patients can be considered ‘clinically’ cured and their progression into blast crisis (BC) a rare event. However, a therapy for those patients who transform is still lacking, and TKIs do not eradicate CML at the stem cell level, therefore leaving a reservoir of cancer stem cells in a dormant stage. Thus, it is not surprising that the focus of CML research has shifted significantly toward the dissection of the mechanisms regulating the survival and self-renewal of TKI-resistant Philadelphia-positive leukemic chronic phase and BC stem cells, with the ultimate goal of developing small molecules capable of selectively killing leukemic but not normal hematopoietic stem cells, thereby achieving a ‘biological’ cure for this disease.

    更新日期:2019-11-18
  • Minimal residual disease
    Leuk. Suppl. Pub Date : 2012-08-09
    D Campana

    The aim of minimal residual disease (MRD) studies in patients with acute leukemia is to measure initial treatment response accurately, provide an assessment of the residual leukemic burden throughout therapy and detect relapse early. Therefore, information resulting from MRD monitoring can substantially improve many facets of clinical management. Methods for MRD detection, namely flow cytometry and PCR, have been applied to study the remission status of thousands of patients with acute lymphoblastic leukemia and acute myeloid leukemia. Collectively, the data indicate that MRD is a powerful prognostic indicator and an indispensable parameter for risk-adapted therapy. The current status of MRD in acute leukemia is briefly reviewed in this paper.

    更新日期:2019-11-18
  • Management of Philadelphia chromosome-positive acute lymphoblastic leukemia
    Leuk. Suppl. Pub Date : 2012-08-09
    O G Ottmann

    Tyrosine kinase inhibitors (TKIs) directed against the ABL kinase are now used routinely during frontline therapy for Philadelphia chromosome-positive acute lymphoblastic leukemia (Ph+ALL) and result in hematologic remission rates exceeding 90%. Minimal residual disease levels are generally lower when TKIs are used in combination with chemotherapy rather than as monotherapy. Although outcome has improved substantially with TKI-based regimens compared with historic controls, allogeneic stem cell transplantation (SCT) in first remission provides the best chance of cure for the majority of patients eligible for SCT. Administration of imatinib after SCT further reduces molecular recurrence and is associated with greatly improved relapse-free and overall survival. The high relapse rate in non-transplanted patients is largely attributable to the emergence of leukemic clones with mutations in the tyrosine kinase domain of BCR-ABL. Ongoing studies with newer TKIs will determine whether these more potent agents are able to sustain remissions without SCT. Assessment of minimal residual disease has become an integral part of the management of Ph+ALL, as it has prognostic importance and is used to guide therapeutic intervention. Novel immunotherapeutic interventions and combinations of TKIs are currently being investigated in clinical trials and may further improve the prognosis of patients with Ph+ALL.

    更新日期:2019-11-18
  • Prognostic markers in AML: focus on CBFL
    Leuk. Suppl. Pub Date : 2012-08-09
    R Cairoli, A Beghini, M Turrini, G Bertani, E Morra

    Acute myeloid leukemia (AML) is a heterogeneous disease increasing in frequency owing to an aging population. Decisions on intensive induction treatments, intensification and allografting rely on the ability to divide an apparently homogeneous group according to risk. A wide range of clinical, cytogenetic and molecular variables may be used to inform this task; here we examine those variables useful in assessing prognosis for a patient with non-acute promyelocitic AML focusing on core binding factor leukemia. In clinical practice, when counseling an individual patient with AML, a range of well-known clinical variables (age, performance status and tumor burden) and genetic variables (cytogenetic and gene mutation) must be considered to better define the prognostic risk.

    更新日期:2019-11-18
  • Treating older patients with AML
    Leuk. Suppl. Pub Date : 2012-08-09
    S Amadori

    The treatment of older patients with acute myeloid leukemia is a difficult challenge. Older adults are more likely to have comorbidities that can limit treatment options, the disease tends to be more aggressive biologically and outcomes are worse than those in younger patients. Deciding which older patients would benefit from intensive chemotherapy is difficult, and efforts are underway to improve existing risk-assessment tools. Treatment should be individualized and may include standard chemotherapy for those patients who have none or at most one adverse factor, or investigational agents for those presenting with multiple poor-risk features. Low-intensity therapies are recommended for those patients who are deemed too frail to tolerate myelosuppressive regimens.

    更新日期:2019-11-18
  • 更新日期:2019-11-18
  • 更新日期:2019-10-08
  • Myeloid differentiation and the leukemia-initiating cell
    Leuk. Suppl. Pub Date : 2014-12-17
    D G Tenen

    Special Report

    更新日期:2019-07-05
  • 更新日期:2019-07-05
  • 更新日期:2019-07-05
  • STAT3 as a mediator of BCR-ABL1-independent resistance in chronic myeloid leukemia
    Leuk. Suppl. Pub Date : 2014-12-17
    A M Eiring, I L Kraft, B D Page, T O'Hare, P T Gunning, M W Deininger

    Special Report

    更新日期:2019-07-05
  • New Abelson interactor-1 (Abi-1)-driven mechanism of acquired drug resistance
    Leuk. Suppl. Pub Date : 2014-12-17
    A Chorzalska, P M Dubielecka

    Special Report

    更新日期:2019-07-05
  • Adult marrow hematopoiesis: a continuum of change
    Leuk. Suppl. Pub Date : 2014-12-17
    P J Quesenberry, L Goldberg, M Dooner, M Pereira, J Aliotta

    Special Report

    更新日期:2019-07-05
  • Deconvoluting MLL1-dependent pathways in hematopoiesis and leukemogenesis
    Leuk. Suppl. Pub Date : 2014-12-17
    B P Mishra, P Ernst

    Special Report

    更新日期:2019-07-05
  • 更新日期:2019-05-16
  • Adoptive immunotherapy for myeloid malignancies
    Leuk. Suppl. Pub Date : 2014-12-17
    J L Reagan

    Special Report

    更新日期:2019-05-16
  • 更新日期:2019-05-16
  • The polycythemia vera stem cell
    Leuk. Suppl. Pub Date : 2014-12-17
    J L Spivak

    Special Report

    更新日期:2019-05-16
  • 更新日期:2019-05-16
  • 更新日期:2019-05-16
  • 更新日期:2019-05-16
  • 更新日期:2019-05-16
  • 更新日期:2019-05-16
  • 更新日期:2019-05-16
Contents have been reproduced by permission of the publishers.
导出
全部期刊列表>>
限时免费阅读临床医学内容
ACS材料视界
科学报告最新纳米科学与技术研究
清华大学化学系段昊泓
自然科研论文编辑服务
中国科学院大学楚甲祥
中国科学院微生物研究所潘国辉
中国科学院化学研究所
课题组网站
X-MOL
北京大学分子工程苏南研究院
华东师范大学分子机器及功能材料
中山大学化学工程与技术学院
试剂库存
天合科研
down
wechat
bug